← Back to Search

Blood Test

Point of Care HbA1c as a Screening Test for Type 2 Diabetes in First Nations

N/A
Waitlist Available
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group

Summary

1. Purpose * to estimate the prevalence of undiagnosed diabetes mellitus and pre-diabetes in a BC First Nation community * to determine the utility of community based screening by examining how many positively screened people follow up with the recommended subsequent testing and family physician visit * to determine if point-of-care HbA1c test (Ames/Bayer DCA 2000) correlates with the confirmatory fasting and 2 hour post challenge blood glucose tests. 2. Hypothesis The Point-of-Care test will correlate well with the gold standard diagnostic tests and prove to be a useful tool for community-based screening. This test obviates the need for fasting and repeat glucose tolerance testing.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Does the HbA1c identify the same individuals as fasting and 2-hr pc glucose tests to identify diabetes and pre-diabetes in a First Nation community
Secondary study objectives
Provide estimates of prevalence of diabetes and prediabetes in a First Nation community
To identify the response rate of "gold standard" diabetes testing in a First nation community

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All volunteers have HbA1c testExperimental Treatment4 Interventions
All candidates receive same procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood test
2019
Completed Phase 3
~16130

Find a Location

Who is running the clinical trial?

Vancouver General HospitalOTHER
41 Previous Clinical Trials
19,355 Total Patients Enrolled
University of British ColumbiaLead Sponsor
1,481 Previous Clinical Trials
2,494,596 Total Patients Enrolled
Jessica MacKenzie-Feder, MDStudy DirectorUniversity of British Columbia
Sandra Sirrs, MDStudy DirectorUniversithy of British Columbia
1 Previous Clinical Trials
6 Total Patients Enrolled
~22 spots leftby Dec 2025